https://www.stjude.org/research/progress/2018/loxo-101-larotrectinib-response-rates-for-solid-tumors-with-ntrk-gene-fusion.html
Newly approved Vitrakvi (larotrectinib) scored high patient response rates by inhibiting a rare chromosomal abnormality that drives tumor growth.
targeted therapylarotrectinibcouldmaketumors
https://www.illumina.com/ko-kr/science/genomics-podcast/testing-for-ntrk-fusions.html
Vivek Subbiah, MD, explains how patients with rare and common tumors can be...
testingntrkfusions